Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk

British Journal of Clinical Pharmacology

Volumn 45, Issue 5, 1998, Pages 459-462

  Ilett, K F ^a,b   Hackett, L P ^b   Dusci, L J ^b   Roberts, M J ^c   Kristensen, J H ^c   Paech, M ^d   Groves, A ^e   Yapp, P ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Western Australian Centre for Pathology and Medical Research   (Australia)

^c King Edward Mem Prncs Margaret H   (Australia)

^d KING EDWARD MEMORIAL HOSPITAL   (Australia)

^e GRAYLANDS HOSPITAL   (Australia)

Author keywords

Human milk; Infant dose; Milk; Plasma ratio; Venlafaxine

Indexed keywords

DESVENLAFAXINE; DRUG METABOLITE; VENLAFAXINE;

ARTICLE; BREAST FEEDING; CASE REPORT; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG MILK LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; BREAST FEEDING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANOLS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MILK, HUMAN; TISSUE DISTRIBUTION;

EID: 0031959755     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00710.x     Document Type: Article

References (16)

1. Morton WA, Sonne SL, Verga MA. Venlafaxine: a structurally unique and novel antidepressant. Ann Pharmacother 1995; 29: 387-395.
2. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280-294.
3. Lecrubier Y. Clinical utility of venlafaxine in comparison with other antidepressants. [Review]. Int Clin Psychopharmacol 1995; 10: Suppl 2: 29-35.
4. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses Br J Psychiat 1987; 150: 662-673.
5. Kessler RC, McGonagle KA, Zhoo S, et al. Arch Gen Psychiat Lifetime and 12 month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. 1994; 51: 8-19.
6. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996 153: 1132-1137.
7. Troy SM, Parker VD, Fruncillo RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995; 35: 404-409.
8. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716-724.
9. Wang CP, Howell SR, Scatina J, Sisenwine SF. The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine. Chirality 1992; 4: 84-90.
10. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxinc oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149-156.
11. Troy SM, Schultz RW, Parker VD, Chiang ST, Blum RA. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994; 56: 14-21.
12. Bennett PN. Use of the monographs on drugs. In Drugs and human lactation,. 2nd Edn, Ed Bennett PN, Amsterdam: Elsevier, 1996: pp. 67-74.
13. Baum AL, Misri S. Selective serotonin-reuptake inhibitors in pregnancy and lactation. Harvard Rev Psychiat 1996; 4: 117-125.
14. Begg EJ, Atkinson HC, Duffull SB. Prospective evaluation of a model for the prediction of milk: plasma drug concentrations from physicochemical characteristics. Br J Clin Pharmacol 1992; 33: 501-505.
15. Buist A, Janson H. Effect of exposure to dothiepin and northiaden in breast milk on child development. Br J Psychiat 1995; 167: 370-373.
16. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-262.